Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
The purpose of this study is to test the safety and side effects of SGN-LIV1A and pembrolizumab when used together, as well as how well they work against triple negative breast cancer that has spread to other parts of the body. Investigators may test different doses of SGN-LIV1A to find the best one to use with pembrolizumab.
- Evaluate the safety and tolerability of the combination of SGN-LIV1A and pembrolizumab in patients with locally-advanced or metastatic, triple-negative breast cancer (LA/M TNBC). - Identify the recommended dose of SGN-LIV1A in combination with pembrolizumab in patients with LA/MTNBC. - Evaluate confirmed objective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 of the combination of SGN-LIV1A and pembrolizumab in patients with LA/M TNBC.
Pembrolizumab (Keytruda); SGN-LIV1A ()
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.